Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Background. Nitric oxide (NO) deficiency contributes to chronic kidney disease (CKD)
progression and hypertension. The β-blocker, nebivolol (N), also enhances NO production …

Nebivolol is a new selective beta 1‐adrenoceptor antagonist with nitric oxide (NO)–
releasing properties. In the present study we have analyzed whether nebivolol affects the …

Nebivolol is a beta blocker with a unique function which distinguishes it from other beta
blockers. It increases the release of nitric oxide (NO) which produces vasodilatation and …

Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile
dysfunction, vascular disease, and diabetes mellitus. This review investigated the data …

Nebivolol is a β-blocker under US Food and Drug Administration review for the treatment of
hypertension. The unique pharmacologic properties of nebivolol include high specificity for …

Background Nebivolol is a third-generation beta-blocker used to treat hypertension. The
vasodilation properties of nebivolol have been attributed to nitric oxide (NO) release …

Background and Objectives: Hypertension is a widely prevalent con-dition of elevated blood
pressure (BP) and is the leading risk factor for the development of cardiovascular disease …

Nebivolol is a new cardioselective beta-blocking agent possessing vasodilatory properties
involving the endothelium. This compound is a dl-racemic mixture. The d-enantiomer is …

Objective To obtain further insight into the mechanism underlying the vasodilator effect of
nebivolol. Since oxidative inactivation of nitric oxide (NO) is regarded as an important cause …